Between May of 2001 and November of 2009, I was an invited visiting professor teaching joint replacement surgery in 76 cities around the world at hospitals, in operating rooms, and at orthopedic conferences in 37 countries including Japan, China, Singapore, Russia, Turkey, Israel, Jordan, Lebanon, Qatar, The United Arab Emirates, Saudi Arabia, Bahrain, North Africa, and the emerging newly independent countries of Central and Eastern Europe. My introduction of American joint replacement methodology extended through most of Asia, Central and Eastern Europe, North Africa and the Middle East. During that span, I hosted in Chicago, several hundred visiting orthopedic surgeons from around the globe to teach them my joint replacement techniques as well introduce basic arthroplasty technique, minimally invasive surgery and new prosthetic made in America designs. I still maintain active scientific exchange serving on the editorial board of orthopedic journals both in Serbia and Poland. All these initiatives have provided me with the unusual opportunity not only to stay abreast of and participate in orthopedic developments in the United States but to stay on top of the orthopedic developments around the world. It is time I believe to adopt an Active Ageing approach to orthopedics in this country and that’s why my Blog has been so directed over the past 36 months.
It has taken us almost three years of study and global observation to allow for announcement of a Pilot Study for the treatment of arthritic joints with Bone Marrow Concentrate; now is the time. Last week, I used my Blog to announce the opening of The Regenerative Pain Center with the sole purpose being an attempt at pain control through Regenerative Medicine in contrast to operative intervention. This week, I am announcing the start up of the first Pilot Study made possible because of the Regenerative Pain Center. A Pilot Study is the standard scientific tool for “soft” research, allowing me to conduct a preliminary analysis before committing to a full-blown clinical trial. I will investigate the validity of Bone Marrow Concentrate in treating arthritis of the hip or the knee in compliance with the FDA governance as described in CFR21 Part 1271 falling under the same day surgical exemption discussed in 1271.15(b).
To date, it has been patient testimonials and anecdote supporting regenerative medical care in the musculoskeletal system. That’s all changing, yesterday I received a new course announcement from the American Academy of Orthopedic Surgeons in Phoenix, April 20 to 22, titled Advances in Care of the Aging Athlete. Among the hot topics will be stem cell updates.The course will cover a broad array of topics, including degenerative, arthritic, and traumatic conditions that result from injuries, and take an expanded approach to the treatment of aging female athletes. I will use this course to help me better counsel active patients on managing their participation in sports as they age. Christopher J. Centeno, MD has gone further than anyone in this country, to the best of my knowledge, in advancing the regenerative field with his publication of Orthopedics 2.0. How Regenerative Medicine will Create the Next Generation of Less Invasive Orthopedics.
My intent is to advance the scientific process with the introduction of a pilot study using Bone Marrow Concentrate in the hip and the knee. Next week I will focus on the several pilot studies and who qualifies.
Mitchell B. Sheinkop, M.D.
1565 N. LaSalle Street
Chicago, Illinois 60610